ZYDUS LIFESCIENCES Financial Statement Analysis
|
||
The Revenues of ZYDUS LIFESCIENCES have increased by 13.40% YoY .
The Earnings Per Share (EPS) of ZYDUS LIFESCIENCES has increased by 98.04 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
ZYDUS LIFESCIENCES Last 5 Annual Financial Results
[BOM: 532321|NSE : ZYDUSLIFE]
Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹19,547 Cr | ₹17,237 Cr | ₹15,110 Cr | ₹14,404 Cr | ₹14,253 Cr |
Expenses | ₹14,248 Cr | ₹13,666 Cr | ₹11,935 Cr | ₹11,018 Cr | ₹11,473 Cr |
Operating Profit (Excl OI) | ₹5,299 Cr | ₹3,572 Cr | ₹3,175 Cr | ₹3,385 Cr | ₹2,780 Cr |
Other Income | ₹369 Cr | ₹475 Cr | ₹391 Cr | ₹75 Cr | ₹117 Cr |
Interest | ₹81 Cr | ₹130 Cr | ₹127 Cr | ₹186 Cr | ₹342 Cr |
Depreciation | ₹764 Cr | ₹723 Cr | ₹713 Cr | ₹670 Cr | ₹697 Cr |
Profit Before Tax | ₹4,809 Cr | ₹2,590 Cr | ₹2,838 Cr | ₹2,399 Cr | ₹1,495 Cr |
Profit After Tax | ₹3,831 Cr | ₹2,002 Cr | ₹2,326 Cr | ₹2,206 Cr | ₹1,176 Cr |
Consolidated Net Profit | ₹3,860 Cr | ₹1,960 Cr | ₹4,487 Cr | ₹2,134 Cr | ₹1,177 Cr |
Earnings Per Share (Rs) | ₹38.36 | ₹19.37 | ₹43.82 | ₹20.84 | ₹11.49 |
PAT Margin (%) | 10.10 | 5.90 | 7.87 | 7.64 | 8.25 |
ROE(%) | 20.52 | 11.60 | 15.51 | 18.88 | 11.32 |
ROCE(%) | 24.90 | 13.64 | 15.30 | 14.38 | 10.02 |
Total Debt/Equity(x) | 0.04 | 0.07 | 0.25 | 0.35 | 0.77 |
Key Financials |
||
Market Cap | : | ₹ 97,963.6 Cr |
Revenue (TTM) | : | ₹ 21,483.5 Cr |
Net Profit(TTM) | : | ₹ 4,298.9 Cr |
EPS (TTM) | : | ₹ 42.7 |
P/E (TTM) | : | 22.8 |
Industry Peers & Returns | 1W | 1M | 1Y |
ZYDUS LIFESCIENCES | 7% | -0.2% | 27.5% |
SUN PHARMACEUTICAL INDUSTRIES | 2.2% | -5.8% | 22.9% |
CIPLA | 1.3% | -4.8% | 9.5% |
DR REDDYS LABORATORIES | 2.2% | -10.9% | -0.6% |
DIVIS LABORATORIES | 4.1% | -7% | 52% |
MANKIND PHARMA | 0.9% | -15.6% | 21.9% |
TORRENT PHARMACEUTICALS | -3.3% | -5.7% | 28.7% |
LUPIN | 1.6% | -13.2% | 38.3% |
AUROBINDO PHARMA | 0.5% | -13.4% | 1.9% |
ZYDUS LIFESCIENCES Revenues
[BOM: 532321|NSE : ZYDUSLIFE]
Y-o-Y | 13.40 % |
5 Yr CAGR | 8.22 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹19,547 Cr | 13.40 | |
Mar2023 | ₹17,237 Cr | 14.08 | |
Mar2022 | ₹15,110 Cr | 4.90 | |
Mar2021 | ₹14,404 Cr | 1.06 | |
Mar2020 | ₹14,253 Cr | - |
ZYDUS LIFESCIENCES Operating Profit
[BOM: 532321|NSE : ZYDUSLIFE]
Y-o-Y | 48.35 % |
5 Yr CAGR | 17.50 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹5,299 Cr | 48.35 | |
Mar2023 | ₹3,572 Cr | 12.51 | |
Mar2022 | ₹3,175 Cr | -6.22 | |
Mar2021 | ₹3,385 Cr | 21.76 | |
Mar2020 | ₹2,780 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 30.84 % |
5 Yr CAGR | 8.57 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 27.11% | 30.84 | |
Mar2023 | 20.72% | -1.38 | |
Mar2022 | 21.01% | -10.60 | |
Mar2021 | 23.5% | 20.45 | |
Mar2020 | 19.51% | - |
ZYDUS LIFESCIENCES Profit After Tax
[BOM: 532321|NSE : ZYDUSLIFE]
Y-o-Y | 96.88 % |
5 Yr CAGR | 34.58 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹3,860 Cr | 96.88 | |
Mar2023 | ₹1,960 Cr | -56.31 | |
Mar2022 | ₹4,487 Cr | 110.32 | |
Mar2021 | ₹2,134 Cr | 81.34 | |
Mar2020 | ₹1,177 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 71.19 % |
5 Yr CAGR | 5.19 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 10.1 % | 71.19 | |
Mar2023 | 5.9 % | -25.03 | |
Mar2022 | 7.87 % | 3.01 | |
Mar2021 | 7.64 % | -7.39 | |
Mar2020 | 8.25 % | - |
ZYDUS LIFESCIENCES Earnings Per Share (EPS)
[BOM: 532321|NSE : ZYDUSLIFE]
Y-o-Y | 98.04 % |
5 Yr CAGR | 35.17 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹38 | 98.04 | |
Mar2023 | ₹19 | -55.80 | |
Mar2022 | ₹44 | 110.27 | |
Mar2021 | ₹21 | 81.38 | |
Mar2020 | ₹11 | - |
ZYDUS LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 532321|NSE : ZYDUSLIFE]
Y-o-Y | 82.55 % |
5 Yr CAGR | 25.55 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 24.9% | 82.55 | |
Mar2023 | 13.64% | -10.85 | |
Mar2022 | 15.3% | 6.40 | |
Mar2021 | 14.38% | 43.51 | |
Mar2020 | 10.02% | - |
ZYDUS LIFESCIENCES Share Price vs Sensex
Current Share Price | : | ₹973.6 |
Current MarketCap | : | ₹ 97,963.6 Cr |
Updated EOD on | : | Feb 01,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
ZYDUS LIFESCIENCES | 7% |
-0.2% |
27.5% |
SENSEX | 2.8% |
-3.1% |
9% |
ZYDUS LIFESCIENCES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MOMENTUM | 5.1% | -9.6% | 14.6% |
S&P BSE 150 MIDCAP | 3.6% | -8.2% | 13.3% |
S&P BSE 400 MIDSMALLCAP | 3.5% | -9.1% | 11.2% |
S&P BSE 500 | 3.2% | -5.4% | 9.7% |
S&P BSE 250 LARGEMIDCAP | 3.2% | -4.8% | 10% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 100 ALPHA 30 | 4.8% | -8.6% | 11.5% |
NIFTY NEXT 50 | 4.6% | -8.1% | 15.8% |
NSE QUALITY 30 | 3.5% | -2.1% | 12.1% |
NIFTY 100 EQUAL WEIGHT | 3.4% | -4.7% | 11.9% |
NIFTY500 MULTICAP 50:25:25 | 3.3% | -6.8% | 10.3% |
You may also like the below Video Courses
FAQ about ZYDUS LIFESCIENCES Financials
How the annual revenues of ZYDUS LIFESCIENCES have changed ?
The Revenues of ZYDUS LIFESCIENCES have increased by 13.40% YoY .
How the Earnings per Share (EPS) of ZYDUS LIFESCIENCES have changed?
The Earnings Per Share (EPS) of ZYDUS LIFESCIENCES has increased by 98.04 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs